What is it about?

This paper reports on the opportunistic yeast (Candida) species associated with HIV infection in 2 groups from South Africa and Cameroon and describes their response (or lack of it) to the anti-fungal drugs routinely administered for treatment or prophylaxis.

Featured Image

Why is it important?

Many HIV-associated Candida species have developed a resistance to the azole drugs. Regular reports of species prevalence and antimicrobial profiles are essential to control opportunistic infections in HIV patients.


Africa has the highest rate of HIV infection and opportunistic infections need to be controlled to reduce mortality rates. Regular surveillance of opportunistic pathogens and their susceptibility to drugs routinely available at HIV clinics informs adequate treatment . Failure to do so will result in the spread of resistant species which is highly problematic.

Emerita Professor Charlene WJ Africa
University of the Western Cape

Read the Original

This page is a summary of: Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon, Diagnostic Microbiology and Infectious Disease, June 2014, Elsevier, DOI: 10.1016/j.diagmicrobio.2013.09.016.
You can read the full text:



The following have contributed to this page